[MK-231 (Sulindac) in the treatment of rheumatoid arthritis (author's transl)].
MK-231 (Sulindac), 200-400 mg daily, was given to 25 patients with rheumatoid arthritis. The therapeutic response was good and there were no side effects at all. The drug should be used more frequently than heretofore in the drug treatment of symptoms of rheumatoid arthritis.
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001597:Benzylidene Compounds / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007192:Indenes / Q000627:therapeutic use*; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged
D001597:Benzylidene Compounds; D007192:Indenes; D007213:Indomethacin
MK-231 (Sulindac) in der Behandlung der rheumatoiden Arthritis.